The increased buyback target suggests management views shares as undervalued and expects strong cash generation. Monitor future earnings for cash flow updates and actual execution pace of repurchases. The buyback may provide downside support.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 12 $83.34entry
- T+1 · 6mo ago −0.87%α −1.44% · $82.62
- T+5 · 6mo ago +2.16%α +2.09% · $85.14
- T+20 · 5mo ago +5.80%α +7.53% · $88.17
- T+60 · 3mo ago +15.96%α +11.84% · $96.64
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zimmer Biomet announced an increased share repurchase expectation for FY2026, now targeting up to $1.0 billion in buybacks under its existing $1.5 billion authorization. This represents a $250 million increase from prior capital allocation assumptions, signaling management's confidence in cash flow and commitment to returning capital.
Key Facts
- Company intends to repurchase up to $1.0 billion of shares in FY2026
- Increase of $250 million from prior capital allocation assumption
- Repurchases under existing $1.5 billion authorization approved in February 2026
- No changes to the size, duration or terms of the authorization
Financial Impact
Up to $1.0 billion in share repurchases
Risk Factors
- Actual repurchases depend on market conditions, stock price, and capital availability
- No commitment to execute full $1.0 billion; timing and amount variable
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-218098 |
| Document: zbh-ex99_1.htm | 0001193125-26-218098 |
| Document: 0001193125-26-218098-index-headers.html | 0001193125-26-218098 |
| Document: 0001193125-26-218098-index.html | 0001193125-26-218098 |
| Document: 0001193125-26-218098.txt | 0001193125-26-218098 |
Track record
17 reports on ZBH
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +8.74% at T+60 after the Apr 28, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $103.21 Now $101.41 −1.74% settles Nov 20
- Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
- Nov 9, 20267d ago 424B5 Neutral 3/10 Entry $107.32 Now $101.41 −5.51% settles Nov 17
- Nov 5, 202611d ago 424B5 Neutral 3/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
- Nov 5, 202611d ago 424B5 Neutral 2/10 Entry $106.85 to $104.56 Now $101.41 −5.09% ▼ −2.14% −5.43% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 Entry $110.15 to $107.47 Now $101.41 −7.93% ▼ −2.43% −1.52% vs SPY
- Oct 26, 202621d ago Institutional Cluster Bearish 4/10 Entry $97.44 to $94.52 Now $101.41 −4.07% ▲ +3.00% +1.74% vs SPY
- Oct 21, 202627d ago Court Ruling Bearish 6/10 Entry $98.81 to $97.47 Now $101.41 −2.63% ▲ +1.36% +2.06% vs SPY
- Sep 15, 20268w ago Insider Cluster Neutral 3/10 Entry $96.53 to $90.64 Now $101.41 +5.06% ▼ −6.10% −8.17% vs SPY
- Sep 2, 202610w ago Court Ruling Neutral 2/10 Entry $98.66 to $93.24 Now $101.41 +2.79% ▼ −5.49% −4.34% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers